PTC Therapeutics Inc.
Find Ratings ReportsPTC THERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. PTC THERAPEUTICS INC has strong liquidity. Currently, the Quick Ratio is 1.90 which shows the ability to cover short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 135.83% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 307.06 | 167.41 |
EBITDA ($mil) | 86.03 | -121.79 |
EBIT ($mil) | 5.32 | -160.66 |
Net Income ($mil) | -155.79 | -170.89 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 882.81 | 410.71 |
Total Assets ($mil) | 1895.7 | 1705.62 |
Total Debt ($mil) | 2229.12 | 1461.51 |
Equity ($mil) | -818.56 | -347.09 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 91.67 | 95.35 |
EBITDA Margin | 28.01 | -72.74 |
Operating Margin | 1.73 | -95.97 |
Sales Turnover | 0.49 | 0.41 |
Return on Assets | -33.05 | -32.77 |
Return on Equity | 0.0 | 0.0 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 2.02 | 1.71 |
Debt/Capital | 1.58 | 1.31 |
Interest Expense | 44.28 | 24.5 |
Interest Coverage | 0.12 | -6.56 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 75.71 | 73.11 |
Div / share | 0.0 | 0.0 |
EPS | -2.06 | -2.35 |
Book value / share | -10.81 | -4.75 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 1086441.0 | 1462871.0 |
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is below the S&P 500 average and is well below the subsector average, indicating a discount.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PTCT NM | Peers 85.83 | PTCT NM | Peers 38.76 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. PTCT's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. PTCT's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
PTCT NM | Peers 18.08 | PTCT NA | Peers 1.16 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. PTCT's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
PTCT NM | Peers 19.07 | PTCT -7.31 | Peers 12.58 | |||||||||||||||||||||
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. PTCT's P/B is negative making this valuation measure meaningless. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, PTCT is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
PTCT 2.33 | Peers 84.44 | PTCT 34.20 | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. PTCT is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. PTCT trails its peers on the basis of sales growth. |
|||||||||||||||||||||||